News By Tag
News By Place
Follow on Google News
Bedfont Scientific Ltd receives FDA clearance for NObreath FeNO monitor
Bedfont's NObreath monitor for airway inflammation has been cleared for sale in the USA
By: Bedfont Scientific Ltd
The NObreath, which conforms to ATS and ERS guidelines, is a portable, non-invasive device for the measurement of Fractional Exhaled Nitric Oxide (FeNO) in human breath. The production of nitric oxide is often found to be increased in inflammatory conditions such as asthma.
The NObreath works by measuring FeNO through breath analysis, making the process quick, simple, and non-invasive for both the Healthcare Professional and the patient. Interpreting FeNO levels aids in identifying patients who do/do not require ongoing treatment whilst also differentiating between allergic (eosinophilic)
Jason Smith, Managing Director at Bedfont, comments, "NObreath has been available outside the US for over 12 years now, we have been working towards FDA clearance for quite some time and we are over the moon to have received it. We are one step closer to achieving our purpose; to make FeNO monitoring lower cost and therefore more accessible globally. According to the Centre for Disease Control (CDC), around 25 million Americans suffer from asthma; that's a potential 25 million people that the NObreath® can help through FeNO monitoring."
Bedfont Scientific Ltd